Trial · NCT06425419
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
NCT06425419, Phase 1, Not yet recruiting, Massachusetts Eye and Ear Infirmary
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy. Trials, record NCT06425419. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06425419
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
- NCT number
- NCT06425419
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Conditions
- Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy, Rhegmatogenous Retinal Detachment
- Interventions
- Topotecan
- First posted
- 2024-05-22
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence of rhegmatogenous retinal detachment secondary to PVR | 6 months after initial surgery, or last follow-up visit available | Investigators will be evaluating whether participant develop a recurrent retinal detachment throughout their follow up after their initial surgery. |
| Secondary | Best corrected visual acuity (BCVA) | at the pre-operative assessment, and post-operative day1, 7, 28, 56, 84, 126, 168 | Investigators will be measuring the BCVA of participants throughout their follow up and see if they notice any change from surgery time to final follow up |
| Secondary | Variation of PVR grade | at the pre-operative assessment, and post-operative day1, 7, 28, 56, 84, 126, 168 | Investigators will be doing a dilated fundus exam and taking fundus photographies for all participants throughout their follow up time to see if the grade of the PVR changes over time. PVR grade goes from grade A to grade C-Anterior to equator/ C-Posterior to equator (grade C being worse than grade A) |
| Secondary | Retinal reattachment rate at month 6 or last follow up | at post-operative day 168 (or last follow-up visit available if the participant did not show up at post-operative day 168) | Investigators will be doing a dilated fundus exam and taking fundus photographies for all participants throughout their follow up time to see if the retinal reattaches (whether completely or partially) after surgery |
| Secondary | Recurrence of rhegmatogenous retinal detachment due to any cause | at the pre-operative assessment, and post-operative day1, 7, 28, 56, 84, 126, 168 | Investigators will be measuring the BCVA of participants throughout their follow up and see if they notice any change from surgery time to final follow up |
| Secondary | Number of participants and type of intraoperative or postoperative complications | at time of surgery, and each follow up visit (post-operative day1, 7, 28, 56, 84, 126, 168) | Any adverse event will be noted during surgery, and at each follow up visit for each participant if applicable. |
| Other | Optical coherence tomography (OCT) of the macula | at the pre-operative assessment, and post-operative day1, 7, 28, 56, 84, 126, 168 | an OCT of the macula will be taken to evaluate for any retinal changes throughout the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06425419
GET https://conductscience.org/api/trials/v1/NCT06425419/registered